18 results with keyword: 'intravitreal bevacizumab vascular endothelial management complications proliferative retinopathy'
Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group
N/A
The first goal of this paper was to determine whether chronic exposure to mild decreased oxygen (15% O 2 ) induces the HIF signaling system in blood vessels. The sec- ond goal was
N/A
Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal
N/A
Purpose: To investigate the effect of bevacizumab (Avastin; Genentech, San Francis- co, CA, USA) on vascular endothelial growth factor (VEGF) expression and inflam- mation
N/A
VEGF: vascular endothelial growth factor; DR: diabetic retinopathy; DME: diabetic macular edema; NPDR: non-proliferative diabetic retinopathy; PDR: proliferative diabetic
N/A
Keywords: vascular endothelial growth factor, retinopathy of prematurity, intravitreal neovas- cularization, oxygen-induced retinopathy model, physiological retinal
N/A
injections for the prevention of post-vitrectomy complications in proliferative diabetic retinopathy (PDR) patients with elevated vitreous vascular endothelial growth factor
N/A
Risk Factors for the Development or Progression of Tractional Retinal Detachment following Intravitreal Bevacizumab (Avastin) in Patients with Severe Proliferative
N/A
Strong community partnerships between the local Aboriginal or Islander community and school staff is vital to embed Aboriginal and Torres Strait Islander perspectives across
N/A
During both physio- logical retinal vascular development (1) and pathological proliferative retinopathy (2), new blood vessel growth is regulated by vascular endothelial growth
N/A
Mainstream primary care services, such as private general practices and community health clinics, also have a strong potential to improve the quality of the primary care they
N/A
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd... the median control group risk across studies) is provided in footnotes.. The corresponding
N/A
From the steady state simulation results and harmonic spectra of line currents, it can be concluded that the proposed DSVM based vector control algorithm gives
N/A
In recent years, the use of intravitreal anti- vascular endothelial growth factor (anti-VEGF) agents, Bevacizumab (Avastin) (Genentech, USA), Ranibizumab (Lucentis),
N/A
Focus groups occurred in four groups; the first was nine Nominating Committee members, the second was the three adult advisors to the Committee, the third was five members of
N/A
In this study, we evaluated the safety and effectiveness of cataract surgery and simultaneous intravitreal anti- vascular endothelial growth factor (bevacizumab or
N/A
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age- related
N/A
This program aims to improve the care Aboriginal and Torres Strait Islander people receive after a stroke or brain injury, improve the health of Aboriginal and Torres Strait
N/A